


Curriculum Vitae

Name	Dong-Wan Kim	
Current Position & Affiliation	Professor Seoul National University Hospital	
Country	Republic of Korea	

Educational Background

- 1994.2 M.D.
Seoul National University, Seoul, Korea
2007.2 Ph.D.
Seoul National University, Seoul, Korea

Professional Experience

- 2017-Current Professor
Seoul National University College of Medicine, Seoul, Korea
2008~2017 Assistant and Associate Professor
Seoul National University College of Medicine, Seoul, Korea
2008~2009 Research Fellow
Duke Comprehensive Cancer Center, NC, USA
2003~2008 Clinical Professor
Seoul National University Hospital, Seoul, Korea
2002~2003 Clinical Fellow
Seoul National University Hospital, Seoul, Korea
1994~1999 Internship and Residency in Internal Medicine
Seoul National University Hospital, Seoul, Korea

Professional Organizations

- Domestic: KSMO, KCA, KALC
International: ASCO, ESMO, AACR, IASLC

Main Scientific Publications

Kim DW, Kim HG, Kim JH, et al. Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer. *Cancer Res Treat* 2019;51:119-127.

Kim DW, Lee DH, Han JY, et al. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. *Lung Cancer* 2019;135:66-72.

Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Lee JS, Hochmair MJ, Li YC, Chang GC, Lee KH, Gridelli C, Delmonte A, Campelo RG, Kim DW, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. *N Engl J Med* 2018;379:2027-39.

Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in Patients with Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. *J Clin Oncol* 2017;35:2490-98.

Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol* 2016; 17:452-63.

Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. *J Clin Oncol* 2016;34:661-8.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387:1540-50.